The 'PDMED' trial


15 Apr 2015

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial.PD MED Collaborative Group*Summary Background Whether initial treatment for Parkinson’s disease should consist of levodopa, dopamine agonists, or monoamine oxidase type B inhibitors (MAOBI) is uncertain. We aimed to establish which of these three classes of drug, as initial treatment, provides the most effective long-term control of symptoms and best quality of life for people with early Parkinson’s disease. PDMED
Published Online June 11, 2014 http://dx.doi.org/10.1016/ S0140-6736(14)60683-8
See Online/Comment http://dx.doi.org/10.1016/ http://dx.doi.org/10.1016/ S0140-6736(14)60962-4*Members listed at end of paperCorrespondence to: PD MED Trial Office, Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, Robert Aitken Institute for Clinical Research, University of Birmingham, Birmingham B15 2TT, UK PD-trials@bham.ac.uk
'The things you can't get from the books'

Parkinson's Academy, our original and longest running Academy, houses 19 years of inspirational projects, resources, and evidence for improving outcomes for people with Parkinson's. Led by co-founder and educational director Dr Peter Fletcher, the Academy has a truly collegiate feel and prides itself on delivering 'the things you can't get from books' - a practical learning model which inspires all Neurology Academy courses.